Dr. Goodman is Chief Executive Officer of Pharmascience Inc., a Canadian fully-integrated pharmaceutical company involved in the development, manufacture and distribution of a broad line of generic and branded products. Under Dr. Goodman’s leadership, Pharmascience has grown to become a top ten Canadian Pharmaceutical company, the third largest pharmaceutical company in Canada by number of prescriptions with a diversified portfolio of over 340 product families and sales in more than 60 countries. David obtained his Bachelor of Commerce degree from McGill and a Ph.D. in pharmacology from the University of Virginia. He began his career at Pharmascience in Business Development and prior to being appointed CEO he was Executive Vice President, Pharmascience International.
SmPill® is the main focus of Sigmoid’s current development work and underpins all product development programmes. CyCol®, Sigmoid’s lead clinical development program, which is advancing into Phase 3 trials for moderate to severe ulcerative colitis, was uniquely enabled using SmPill® drug delivery technology.